Skip to main content
Top
Published in: Journal of Neurology 9/2017

01-09-2017 | Original Communication

Severe refractory CIDP: a case series of 10 patients treated with bortezomib

Authors: Kalliopi Pitarokoili, Min-Suk Yoon, Ilka Kröger, Anke Reinacher-Schick, Ralf Gold, Christiane Schneider-Gold

Published in: Journal of Neurology | Issue 9/2017

Login to get access

Abstract

Treatment options for patients with aggressive chronic inflammatory demyelinating neuropathy are limited and include the anti-CD20 antibody rituximab and the immunosuppressive regime cyclophosphamide. We aimed to investigate retrospectively the efficacy of bortezomib, a proteasome inhibitor tackling highly metabolically active cell types such as plasma cells, in a case series of 10 treatment refractory CIDP patients. All patients reported showed a deterioration of the clinical CIDP scores under first-line treatment or escalating treatment with cyclophosphamide or rituximab. One or two cycles of bortezomib treatment (each cycle with 1.3 mg/m2 administered s.c. on days 1, 4, 8, and 11) stabilized the majority of the patients (n = 6) during treatment and even improved clinical and electrophysiological parameters of four patients up to 1 year later. No relevant side-effects were reported. Two patients received autologous peripheral blood stem cell transplantation after bortezomib, which led to fatal infections. We conclude that bortezomib could be an attractive escalating treatment option with a good side-effect profile for patients with treatment refractory CIDP.
Appendix
Available only for authorised users
Literature
1.
go back to reference Austin JH (1958) Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain 81(2):157–192CrossRefPubMed Austin JH (1958) Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain 81(2):157–192CrossRefPubMed
2.
go back to reference Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV (1975) Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50(11):621–637PubMed Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV (1975) Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50(11):621–637PubMed
4.
go back to reference Lunn MP, Manji H, Choudhary PP, Hughes RA, Thomas PK (1999) Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 66:677–680CrossRefPubMedPubMedCentral Lunn MP, Manji H, Choudhary PP, Hughes RA, Thomas PK (1999) Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 66:677–680CrossRefPubMedPubMedCentral
5.
go back to reference Laughlin RS, Dyck PJ, Melton LJ III, Leibson C, Ransom J, Dyck PJ (2009) Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 73:39–45CrossRefPubMedPubMedCentral Laughlin RS, Dyck PJ, Melton LJ III, Leibson C, Ransom J, Dyck PJ (2009) Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 73:39–45CrossRefPubMedPubMedCentral
6.
go back to reference Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society–first revision. J Peripher Nerv Syst 15(3):185–195CrossRef Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society–first revision. J Peripher Nerv Syst 15(3):185–195CrossRef
7.
go back to reference Sanvito L, Makowska A, Gregson N, Nemni R, Hughes RA (2009) Circulating subsets and CD4(+) CD25(+) regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy. Autoimmunity 42(8):667–677CrossRefPubMed Sanvito L, Makowska A, Gregson N, Nemni R, Hughes RA (2009) Circulating subsets and CD4(+) CD25(+) regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy. Autoimmunity 42(8):667–677CrossRefPubMed
8.
go back to reference Lopate G, Pestronk A, Al-Lozi M (2005) Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 62(2):249–254CrossRefPubMed Lopate G, Pestronk A, Al-Lozi M (2005) Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Arch Neurol 62(2):249–254CrossRefPubMed
9.
go back to reference van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, Faber CG, van Oostrom JC, Vogels OJ, Hadden RD, Kleine BU, van Norden AG, Verschuuren JJ, Dijkgraaf MG, Vermeulen M (2010) Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 9(3):245–253CrossRefPubMed van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, Faber CG, van Oostrom JC, Vogels OJ, Hadden RD, Kleine BU, van Norden AG, Verschuuren JJ, Dijkgraaf MG, Vermeulen M (2010) Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol 9(3):245–253CrossRefPubMed
10.
go back to reference Dyck PJ, O’Brien P, Swanson C, Low P, Daube J (1985) Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 35(8):1173–1176CrossRefPubMed Dyck PJ, O’Brien P, Swanson C, Low P, Daube J (1985) Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Neurology 35(8):1173–1176CrossRefPubMed
11.
go back to reference Good JL, Chehrenama M, Mayer RF, Koski CL (1998) Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 51(6):1735–1738CrossRefPubMed Good JL, Chehrenama M, Mayer RF, Koski CL (1998) Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 51(6):1735–1738CrossRefPubMed
12.
go back to reference Barnett MH, Pollard JD, Davies L, McLeod JG (1998) Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 21(4):454–460CrossRefPubMed Barnett MH, Pollard JD, Davies L, McLeod JG (1998) Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 21(4):454–460CrossRefPubMed
13.
go back to reference Brannagan TH 3rd, Pradhan A, Heiman-Patterson T, Winkelman AC, Styler MJ, Topolsky DL, Crilley PA, Schwartzman RJ, Brodsky I, Gladstone DE (2002) High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 58(12):1856–1858CrossRefPubMed Brannagan TH 3rd, Pradhan A, Heiman-Patterson T, Winkelman AC, Styler MJ, Topolsky DL, Crilley PA, Schwartzman RJ, Brodsky I, Gladstone DE (2002) High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 58(12):1856–1858CrossRefPubMed
14.
go back to reference Gorson KC, Amato AA, Ropper AH (2004) Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 63(4):715–717 (review) CrossRefPubMed Gorson KC, Amato AA, Ropper AH (2004) Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 63(4):715–717 (review) CrossRefPubMed
15.
go back to reference Gladstone DE, Prestrud AA, Brannagan TH 3rd (2005) High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 10(1):11–16CrossRefPubMed Gladstone DE, Prestrud AA, Brannagan TH 3rd (2005) High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst. 10(1):11–16CrossRefPubMed
16.
go back to reference Radziwill AJ, Schweikert K, Kuntzer T, Fuhr P, Steck AJ (2006) Mycophenolate mofetil for chronic inflammatory demyelinating polyradiculoneuropathy: an open-label study. Eur Neurol 56(1):37–38 (Epub 2006 Aug 17) CrossRefPubMed Radziwill AJ, Schweikert K, Kuntzer T, Fuhr P, Steck AJ (2006) Mycophenolate mofetil for chronic inflammatory demyelinating polyradiculoneuropathy: an open-label study. Eur Neurol 56(1):37–38 (Epub 2006 Aug 17) CrossRefPubMed
17.
go back to reference Mahdi-Rogers M, van Doorn PA, Hughes RA (2013) Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 14(6):CD003280 Mahdi-Rogers M, van Doorn PA, Hughes RA (2013) Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 14(6):CD003280
18.
go back to reference Harvey GK, Gold R, Hartung HP, Toyka KV (1995) Non-neural-specific T lymphocytes can orchestrate inflammatory peripheral neuropathy. Brain 118(Pt5):1263–1272CrossRefPubMed Harvey GK, Gold R, Hartung HP, Toyka KV (1995) Non-neural-specific T lymphocytes can orchestrate inflammatory peripheral neuropathy. Brain 118(Pt5):1263–1272CrossRefPubMed
19.
go back to reference Yan WX, Taylor J, Andrias-Kauba S, Pollard JD (2000) Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol 47(6):765–775CrossRefPubMed Yan WX, Taylor J, Andrias-Kauba S, Pollard JD (2000) Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol 47(6):765–775CrossRefPubMed
20.
go back to reference Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA, ICE Study Group (2008) Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7(2):136–144. doi:10.1016/S1474-4422(07)70329-0 (erratum in: Lancet Neurol. 2008 Sep;7(9):771) CrossRefPubMed Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA, ICE Study Group (2008) Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7(2):136–144. doi:10.​1016/​S1474-4422(07)70329-0 (erratum in: Lancet Neurol. 2008 Sep;7(9):771) CrossRefPubMed
21.
go back to reference Manso C, Querol L, Mekaouche M, Illa I, Devaux JJ (2016) Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects. Brain 139(Pt 6):1700–1712CrossRefPubMed Manso C, Querol L, Mekaouche M, Illa I, Devaux JJ (2016) Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects. Brain 139(Pt 6):1700–1712CrossRefPubMed
22.
go back to reference Querol L, Nogales-Gadea G, Rojas-Garcia R, Diaz-Manera J, Pardo J, Ortega-Moreno A, Sedano MJ, Gallardo E, Berciano J, Blesa R, Dalmau J, Illa I (2014) Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 82(10):879–886CrossRefPubMedPubMedCentral Querol L, Nogales-Gadea G, Rojas-Garcia R, Diaz-Manera J, Pardo J, Ortega-Moreno A, Sedano MJ, Gallardo E, Berciano J, Blesa R, Dalmau J, Illa I (2014) Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 82(10):879–886CrossRefPubMedPubMedCentral
23.
go back to reference Devaux JJ, Miura Y, Fukami Y, Inoue T, Manso C, Belghazi M, Sekiguchi K, Kokubun N, Ichikawa H, Wong AH, Yuki N (2016) Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 86(9):800–807CrossRefPubMedPubMedCentral Devaux JJ, Miura Y, Fukami Y, Inoue T, Manso C, Belghazi M, Sekiguchi K, Kokubun N, Ichikawa H, Wong AH, Yuki N (2016) Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology 86(9):800–807CrossRefPubMedPubMedCentral
24.
go back to reference Lünemann JD, Nimmerjahn F, Dalakas MC (2015) Intravenous immunoglobulin in neurology–mode of action and clinical efficacy. Nat Rev Neurol 11(2):80–89CrossRefPubMed Lünemann JD, Nimmerjahn F, Dalakas MC (2015) Intravenous immunoglobulin in neurology–mode of action and clinical efficacy. Nat Rev Neurol 11(2):80–89CrossRefPubMed
25.
go back to reference Briani C, Zara G, Zambello R, Trentin L, Rana M, Zaja F (2004) Rituximab-responsive CIDP. Eur J Neurol 11(11):788CrossRefPubMed Briani C, Zara G, Zambello R, Trentin L, Rana M, Zaja F (2004) Rituximab-responsive CIDP. Eur J Neurol 11(11):788CrossRefPubMed
26.
go back to reference Münch C, Anagnostou P, Meyer R, Haas J (2007) Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. J Neurol Sci 256(1–2):100–102CrossRefPubMed Münch C, Anagnostou P, Meyer R, Haas J (2007) Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus. J Neurol Sci 256(1–2):100–102CrossRefPubMed
27.
go back to reference Kosmidis ML, Dalakas MC (2010) Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord. 3(2):93–105CrossRefPubMedPubMedCentral Kosmidis ML, Dalakas MC (2010) Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord. 3(2):93–105CrossRefPubMedPubMedCentral
28.
go back to reference Benedetti L, Briani C, Franciotta D, Fazio R, Paolasso I, Comi C, Luigetti M, Sabatelli M, Giannini F, Mancardi GL, Schenone A, Nobile-Orazio E, Cocito D (2011) Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 82(3):306–308CrossRefPubMed Benedetti L, Briani C, Franciotta D, Fazio R, Paolasso I, Comi C, Luigetti M, Sabatelli M, Giannini F, Mancardi GL, Schenone A, Nobile-Orazio E, Cocito D (2011) Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 82(3):306–308CrossRefPubMed
29.
go back to reference Querol L, Rojas-García R, Diaz-Manera J, Barcena J, Pardo J, Ortega-Moreno A, Sedano MJ, Seró-Ballesteros L, Carvajal A, Ortiz N, Gallardo E, Illa I (2015) Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm 2(5):e149CrossRefPubMedPubMedCentral Querol L, Rojas-García R, Diaz-Manera J, Barcena J, Pardo J, Ortega-Moreno A, Sedano MJ, Seró-Ballesteros L, Carvajal A, Ortiz N, Gallardo E, Illa I (2015) Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm 2(5):e149CrossRefPubMedPubMedCentral
30.
go back to reference Verbrugge SE, Scheper RJ, Lems WF, de Gruijl TD, Jansen G (2015) Proteasome inhibitors as experimental therapeutics of autoimmune diseases. Arthritis Res Ther 28(17):17CrossRef Verbrugge SE, Scheper RJ, Lems WF, de Gruijl TD, Jansen G (2015) Proteasome inhibitors as experimental therapeutics of autoimmune diseases. Arthritis Res Ther 28(17):17CrossRef
31.
go back to reference Wojcik AJ, Skaflen MD, Srinivasan S, Hedrick CC (2008) A critical role for ABCG1 in macrophage inflammation and lung homeostasis. J Immunol 180(6):4273–4282CrossRefPubMed Wojcik AJ, Skaflen MD, Srinivasan S, Hedrick CC (2008) A critical role for ABCG1 in macrophage inflammation and lung homeostasis. J Immunol 180(6):4273–4282CrossRefPubMed
32.
go back to reference Merkies IS, Schmitz PI, van der Meché FG, Samijn JP, van Doorn PA, Inflammatory Neuropathy Cause and Treatment (INCAT) group (2002) Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 72(5):596–601CrossRefPubMedPubMedCentral Merkies IS, Schmitz PI, van der Meché FG, Samijn JP, van Doorn PA, Inflammatory Neuropathy Cause and Treatment (INCAT) group (2002) Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 72(5):596–601CrossRefPubMedPubMedCentral
33.
go back to reference Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K, Islam-Jakobsson P, Malmeström C, Axelsson M, Vågberg M, Sundström P, Lycke J, Piehl F, Svenningsson A (2016) Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology 87(20):2074–2081CrossRefPubMedPubMedCentral Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K, Islam-Jakobsson P, Malmeström C, Axelsson M, Vågberg M, Sundström P, Lycke J, Piehl F, Svenningsson A (2016) Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology 87(20):2074–2081CrossRefPubMedPubMedCentral
34.
go back to reference Greenberg BM, Graves D, Remington G, Hardeman P, Mann M, Karandikar N, Stuve O, Monson N, Frohman E (2012) Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler 18(7):1022–1026CrossRefPubMed Greenberg BM, Graves D, Remington G, Hardeman P, Mann M, Karandikar N, Stuve O, Monson N, Frohman E (2012) Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler 18(7):1022–1026CrossRefPubMed
35.
go back to reference Tiburzy B, Kulkarni U, Hauser AE, Abram M, Manz RA (2014) Plasma cells in immunopathology: concepts and therapeutic strategies. Semin Immunopathol 36(3):277–288CrossRefPubMed Tiburzy B, Kulkarni U, Hauser AE, Abram M, Manz RA (2014) Plasma cells in immunopathology: concepts and therapeutic strategies. Semin Immunopathol 36(3):277–288CrossRefPubMed
36.
go back to reference Manz RA, Thiel A, Radbruch A (1997) Lifetime of plasma cells in the bone marrow. Nature 388(6638):133–134CrossRefPubMed Manz RA, Thiel A, Radbruch A (1997) Lifetime of plasma cells in the bone marrow. Nature 388(6638):133–134CrossRefPubMed
37.
go back to reference Manz RA, Arce S, Cassese G, Hauser AE, Hiepe F, Radbruch A (2002) Humoral immunity and long-lived plasma cells. Curr Opin Immunol 14(4):517–521 (-review) CrossRefPubMed Manz RA, Arce S, Cassese G, Hauser AE, Hiepe F, Radbruch A (2002) Humoral immunity and long-lived plasma cells. Curr Opin Immunol 14(4):517–521 (-review) CrossRefPubMed
38.
go back to reference Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, Voll RE (2008) The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14(7):748–755CrossRefPubMed Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, Voll RE (2008) The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14(7):748–755CrossRefPubMed
39.
go back to reference Bontscho J, Schreiber A, Manz RA, Schneider W, Luft FC, Kettritz R (2011) Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. J Am Soc Nephrol 22(2):336–348CrossRefPubMedPubMedCentral Bontscho J, Schreiber A, Manz RA, Schneider W, Luft FC, Kettritz R (2011) Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. J Am Soc Nephrol 22(2):336–348CrossRefPubMedPubMedCentral
40.
go back to reference Berges C, Haberstock H, Fuchs D, Miltz M, Sadeghi M, Opelz G et al (2008) Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology 124:234–246CrossRefPubMedPubMedCentral Berges C, Haberstock H, Fuchs D, Miltz M, Sadeghi M, Opelz G et al (2008) Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology 124:234–246CrossRefPubMedPubMedCentral
41.
go back to reference Zinser E, Rössner S, Littmann L, Lüftenegger D, Schubert U, Steinkasserer A (2009) Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo. Immunobiology 214:843–851CrossRefPubMed Zinser E, Rössner S, Littmann L, Lüftenegger D, Schubert U, Steinkasserer A (2009) Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo. Immunobiology 214:843–851CrossRefPubMed
42.
go back to reference Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P, CASTOR Investigators (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375(8):754–766CrossRefPubMed Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P, CASTOR Investigators (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375(8):754–766CrossRefPubMed
43.
go back to reference Minarik J, Pavlicek P, Pour L, Pika T, Maisnar V, Spicka I, Jarkovsky J, Krejci M, Bacovsky J, Radocha J, Straub J, Kessler P, Wrobel M, Walterova L, Sykora M, Obernauerova J, Brozova L, Gregora E, Adamova D, Gumulec J, Adam Z, Scudla V, Hajek R (2015) Czech Myeloma Group. Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy. PLoS One 10(4):e0123866CrossRefPubMedPubMedCentral Minarik J, Pavlicek P, Pour L, Pika T, Maisnar V, Spicka I, Jarkovsky J, Krejci M, Bacovsky J, Radocha J, Straub J, Kessler P, Wrobel M, Walterova L, Sykora M, Obernauerova J, Brozova L, Gregora E, Adamova D, Gumulec J, Adam Z, Scudla V, Hajek R (2015) Czech Myeloma Group. Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy. PLoS One 10(4):e0123866CrossRefPubMedPubMedCentral
44.
go back to reference Alé A, Bruna J, Navarro X, Udina E (2014) Neurotoxicity induced by antineoplastic proteasome inhibitors. Neurotoxicology 43:28–35CrossRefPubMed Alé A, Bruna J, Navarro X, Udina E (2014) Neurotoxicity induced by antineoplastic proteasome inhibitors. Neurotoxicology 43:28–35CrossRefPubMed
45.
go back to reference Campo C, Da Silva Filho MI, Weinhold N, Goldschmidt H, Hemminki K, Merz M, Försti A (2016) Genetic susceptibility to bortezomib-induced peripheral neuropathy: replication of the reported candidate susceptibility loci. Neurochem Res 42(3):925–931CrossRefPubMed Campo C, Da Silva Filho MI, Weinhold N, Goldschmidt H, Hemminki K, Merz M, Försti A (2016) Genetic susceptibility to bortezomib-induced peripheral neuropathy: replication of the reported candidate susceptibility loci. Neurochem Res 42(3):925–931CrossRefPubMed
46.
go back to reference Behrendt V, Krogias C, Reinacher-Schick A, Gold R, Kleiter I (2016) Bortezomib treatment for patients with anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol 73:1251–1253CrossRefPubMed Behrendt V, Krogias C, Reinacher-Schick A, Gold R, Kleiter I (2016) Bortezomib treatment for patients with anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol 73:1251–1253CrossRefPubMed
47.
go back to reference Lee HK, Shin YK, Jung J, Seo SY, Baek SY, Park HT (2009) Proteasome inhibition suppresses Schwann cell dedifferentiation in vitro and in vivo. Glia 57(16):1825–1834CrossRefPubMed Lee HK, Shin YK, Jung J, Seo SY, Baek SY, Park HT (2009) Proteasome inhibition suppresses Schwann cell dedifferentiation in vitro and in vivo. Glia 57(16):1825–1834CrossRefPubMed
48.
go back to reference Alé A, Bruna J, Calls A, Karamita M, Haralambous S, Probert L, Navarro X, Udina E (2016) Inhibition of the neuronal NFκB pathway attenuates bortezomib-induced neuropathy in a mouse model. Neurotoxicology 55:58–64CrossRefPubMed Alé A, Bruna J, Calls A, Karamita M, Haralambous S, Probert L, Navarro X, Udina E (2016) Inhibition of the neuronal NFκB pathway attenuates bortezomib-induced neuropathy in a mouse model. Neurotoxicology 55:58–64CrossRefPubMed
Metadata
Title
Severe refractory CIDP: a case series of 10 patients treated with bortezomib
Authors
Kalliopi Pitarokoili
Min-Suk Yoon
Ilka Kröger
Anke Reinacher-Schick
Ralf Gold
Christiane Schneider-Gold
Publication date
01-09-2017
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 9/2017
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-017-8599-4

Other articles of this Issue 9/2017

Journal of Neurology 9/2017 Go to the issue

Pioneers in Neurology

Michael Kremer (1907–1988)